What we do > Human Health

Developing mRNA vaccines and therapies for human health

IN THE PIPELINE

Messenger RNA for vaccines and therapies

Messenger RNA’s features make it broadly valuable for human health. It is well known that mRNA is being used to make effective Covid-19 vaccines that have been developed quickly—critical for pandemic response. GreenLight is working on multiple vaccines and therapeutic uses of mRNA.

IN THE PIPELINE

Vaccines for infectious diseases

Our Covid-19 mRNA vaccine product is in development. We envision a global network of modular manufacturing units that would allow us to commercially produce more than one billion vaccine doses annually, meeting local demand through local production.

Read more

IN THE PIPELINE

Gene therapies

Many genetic diseases have no permanent cure. For example, current treatments for sickle cell disease focus on managing pain and other effects, such as anemia. These treatment regimens are costly, invasive, and impractical. Our RNA-based gene therapy is capable of delivering a healthy copy of the gene to stem cells.

Read more

IN THE PIPELINE

Monoclonal antibodies

We are currently working on early stage development of monoclonal antibodies as a modality.

close up shot of a woman with a clip board
someone writing mrna on a test tube

Why messenger RNA is so powerful

  • Multiple opportunities

    Messenger RNA can be used for both vaccines and therapies.

  • Fast development

    Simple changes to the messenger RNA molecule allow us to make new products quickly.

  • Versatile design

    Simple changes to the messenger RNA molecule allow us to make new products quickly.

a close up of some test tubes in an orange stand
two women work in the Woburn lab

BECOME A PARTNER

We won’t succeed alone

We work with some of the world’s leading universities, companies, and scientists

Learn more

News and insights

The latest on GreenLight’s work and partnerships, and what the world has been saying about us.

All news
  • GreenLight’s honeybee-saving RNA solution named finalist in World Changing Ideas Award

    05.10.22


    GreenLight’s honeybee-saving RNA solution named finalist in World Changing Ideas Award
    GO!
  • International crop network validates ledprona as a new Mode of Action group

    04.05.22


    International crop network validates ledprona as a new Mode of Action group
    GO!
  • Co-developer of COVID-19 Vaccine Joins GreenLight Advisory Board

    03.29.22


    Co-developer of COVID-19 Vaccine Joins GreenLight Advisory Board
    GO!
  • EndPoints: Q&A with GreenLight CEO Andrey Zarur

    03.17.22


    EndPoints: Q&A with GreenLight CEO Andrey Zarur
    GO!
  • BioCentury: GreenLight messenger RNA shingles vaccine deal with Serum Institute of India

    03.14.22


    BioCentury: GreenLight messenger RNA shingles vaccine deal with Serum Institute of India
    GO!
  • Endpoints: GreenLight licenses mRNA shingles vaccine

    03.14.22


    Endpoints: GreenLight licenses mRNA shingles vaccine
    GO!